Terapevticheskii arkhivTerapevticheskii arkhiv0040-36602309-5342LLC Obyedinennaya Redaktsiya3360310.26442/00403660.2019.08.000331Research ArticleEvaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observationKnyazevO V-ShkurkoT V-KagramanovaA V-LishchinskayaA A-ZvyaglovaM Yu-KorneevaI A-BabayanA F-ParfenovA Iasfold@mail.ruLoginov Moscow Clinical Scientific CenterResearch Institute of Health Organization and Medical Management15082019918414616042020Copyright © 2019, Consilium Medicum2019Real - life data on the effectiveness and safety of biosimilar and biologic drugs licensed for treatment of inflammatory bowel diseases (IBD) is lacking. Aim. To investigate efficacy of original Infliximab (IFX) and its biosimilar in treating patients with ulcerative colitis (UC) and determine the frequency of adverse events during 1 year follow - up period. Materials and methods. Our cohort consisted of 98 ulcerative colitis patients, treated with original IFX and its biosimilar since December 2017 till December 2018 years. Original Infliximab was prescribed in 56 UC patients (57.1%) during 5 years and longer; 16 patients (16.3%) were switched to IFX biosimilar; 13 UC bio - naïve patients (13.3%) received original IFX, 29 (29.6%) patients - biosimilar IFX. In 14 patients (14.3%) original infliximab was rotated with biosimilar. We picked out 42 patients to assess efficacy of original IFX and biosimilar. Results and discussion. Twelve patients, received original IFX and 28 patients, treated with its biosimilar, showed significant clinical improvement by decreasing Mayo index from 9.7±0.4 and 10.2±0.2 points to 1.9±0.09 and 2.1±0.1 points, accordingly. Also we noticed positive change in laboratory markers - CRP decrease from 89.6±8.7 mg/l and 77.5±8.0 mg/l to 6.5±0.8 mg/l and 6.9±0.8 mg/l (p>0.05), albumin increase from 30.1±4.7 g/l and 29.6±3.6 g/l to 34.1±6.3 g/l and 32.8±5.9 g/l (p>0.05), increase of serum iron levels from 6.4±0.5 mcg/l and 7.1±0.65 mcg/l to 14.6±4.4 mcg/l and 15.9±5.1 mcg/l (p>0.05), hemoglobin increase from 104.7±9.8 g/l and 102.2±8.8 g/l till 124±11.3 g/l and 121±10.9 g/l (p>0.05), and fecal calprotectin decrease from 1680±134 mcg/g and 1720±126 mcg/g till 245.5±33.4 mcg/g and 230.5±29.8 mcg/g (p>0.05). During 1 year follow - up 12 UC patients, treated with original IFX and its biosimilar, developed adverse events. The majority of adverse events (n=8) were registered in patients, rotating administration of original IFX and its biosimilar. Conclusion. IFX biosimilar is effective as well as original IFX. Frequency of adverse events, occurred in patients, treated with original IFX, was comparable with adverse events frequency in patients, received biosimilar IFX. Frequency of adverse events was significantly higher in UC patients, rotating original IFX and its biosimilar.biosimilarinflammatory bowel diseaseinfliximabulcerative colitisбиосимилярвоспалительные заболевания кишечникаинфликсимабязвенный колит[FDA Guidance for Industry. Scientific considerations in demonstrating bio - similarity to a reference product. 2015.][Declerck P, Danesi R, Petersel D, Jacobs I. The language of biosimilars: clarification, definitions, and regulatory aspects. Drugs. 2017;77(6):671-7.][EMA. Guideline on similar biological medicinal products. 2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768][Yamaguchi T, Arato T. Quality, safety and efficacy of follow - on biologies in Japan. Biologicals. 2011;39(5):328-32.][Jacobs I, Petersel D, Shane L.G, Ng C.K, Kirchhoff C, Finch G, et al. Monoclonal antibody and fusion protein biosimilars across therapeutic areas: a systematic review of published evidence. BioDrugs. 2016;30(6):489-523.][Comparability of biotechnological/biological products subject to changes in their manufacturing process. Available from: https://www.pmda.go.jp/files/ 000156658.pdf][Biosimilars in the EU. 2017. Available from: http://www.ema.europa.eu/docs/en_GB/documentJibrary/Leaflet/2017/05/WC50Q226648.pdf][EMA Guideline. Similar biological medicinal products containing biotechnology - derived proteins as active substance: non - clinical and clinical issues. 2015. Available from: http://www.ema.europa.eu/docs/en_GB/documentJibrary/Scientific_guideline/2015/01 /WC500180219.pdf][Ивашкин В.Т., Шелыгин Ю.А., Халиф И.Л., Белоусова Е.А. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению язвенного колита. Колопроктология. 2017;59(1):6-30.][Brown S.R, Haboubi N, Hampton J, George B, Travis S.P. The management of acute severe colitis: ACPGBI position statement. Colorectal Dis. 2008;(10):8-29.][Mokhele N.N, Tomson S.R, Watermeyer G.A. Predictors of emergency colectomy in patients admitted with acute severe ulcerative colitis. S Afr J Surg. 2017 Sep;55(3):20-6.][Øresland T, Bemelman W.A, Sampietro G.M, Spinelli A, Windsor A, Ferrante M, Marteau P, Zmora O, Kotze P.G, Espin-Basany E, et al. European evidence based consensus on surgery for ulcerative colitis. J Crohn's Colitis. 2015 Jan;9(1):4-25. doi: 10.1016/j.crohns.2014.08.012][Biosimilars in the EU. Available from: https://www.ema.europa.eu/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf.][Biosimilars action plan: balancing innovation and competition. 2018. Available from: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm613761.pdf]